ReviewOncoTargets and therapy2014
Antisense therapeutics in oncology: current status.
Review in OncoTargets and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 54 citations in OpenAlex.
- Development of ARL4C antisense oligonucleotide with reduced off-target effects and enhanced efficacy as an anti-cancer drug.In vitro cellular & developmental biology. Animal · 2026Article
- Long non-coding RNA ZFAS1 promotes the expression of EPAS1 in gastric cardia adenocarcinoma.Journal of advanced research · 2021Article
- Review
- Delivery of antisense oligonucleotide using polyethylenimine-based lipid nanoparticle modified with cell penetrating peptide.Drug delivery · 2019Article
- Reduced miR-125a-5p level in non-small-cell lung cancer is associated with tumour progression.Open biology · 2018Article
- Epigenetic silenced miR-125a-5p could be self-activated through targeting Suv39H1 in gastric cancer.Journal of cellular and molecular medicine · 2018Article
- Current Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs.Molecular diagnosis & therapy · 2018Review
- Microrna-136 promotes proliferation and invasion ingastric cancer cells through Pten/Akt/P-Akt signaling pathway.Oncology letters · 2018Article
- HER3 signaling and targeted therapy in cancer.Oncology reviews · 2018Article
- Prognostic value of microRNAs in gastric cancer: a meta-analysis.Oncotarget · 2017Article
- Natural and artificial small RNAs: a promising avenue of nucleic acid therapeutics for cancer.Cancer biology & medicine · 2017Article
- Article
- Pigmy MicroRNA: surveillance cops in Therapies kingdom.Molecular medicine (Cambridge, Mass.) · 2016Article
- Oncogene Knockdown via Active Loading of Small RNAs into Extracellular Vesicles by Sonication.Cellular and molecular bioengineering · 2016Article
- Delivery strategies and potential targets for siRNA in major cancer types.Advanced drug delivery reviews · 2016Review
- Hematologic malignancies: newer strategies to counter the BCL-2 protein.Journal of cancer research and clinical oncology · 2016Review
- Anti-miR delivery strategies to bypass the blood-brain barrier in glioblastoma therapy.Oncotarget · 2016Article
- Endogenous microRNA sponges: evidence and controversy.Nature reviews. Genetics · 2016Review
- Prognostic value of microRNA-126 and CRK expression in gastric cancer.OncoTargets and therapy · 2016Article
- Approaches to Validate and Manipulate RNA Targets with Small Molecules in Cells.Annual review of pharmacology and toxicology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is increasing progress in translational oncology and tremendous breakthroughs have been made as evidenced by preclinical and clinical trials. Data obtained from high-throughput technologies are deepening our understanding about the molecular and gene network in cancer cells and rapidly emerging in vitro and in vivo evidence is highlighting the role of antisense agents as specific inhibitors of the expression of target genes, thus modulating the response of cancer cells to different therapeutic strategies. Much information is continuously being added into various facets of molecular oncology and it is now understood that overexpression of antiapoptotic proteins, oncogenes, oncogenic microRNAs (miRNA), and fusion proteins make cancer cells difficult to target. Delivery of antisense oligonucleotides has remained a challenge and technological developments have helped in overcoming hurdles by improving the ability to penetrate cells, effective and targeted binding to gene sequences, and downregulation of target gene function. Different delivery systems, including stable nucleic acid lipid particles, have shown potential in enhancing the delivery of cargo to the target site. In this review, we attempt to summarize the current progress in the development of antisense therapeutics and their potential in medical research. We partition this multicomponent review into introductory aspects about recent breakthroughs in antisense therapeutics. We also discuss how antisense therapeutics have shown potential in resensitizing resistant cancer cells to apoptosis by targeted inhibition of antiapoptotic proteins, oncogenic miRNAs, and BCR-ABL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.